Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER(+) breast cancer
Name:
36376284.pdf
Size:
526.7Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Palafox, M.Monserrat, L.
Bellet, M.
Villacampa, G.
Gonzalez-Perez, A.
Oliveira, M.
Brasó-Maristany, F.
Ibrahimi, N.
Kannan, S.
Mina, L.
Herrera-Abreu, M. T.
Òdena, A.
Sánchez-Guixé, M.
Capelán, M.
Azaro, A.
Bruna, A.
Rodríguez, O.
Guzmán, M.
Grueso, J.
Viaplana, C.
Hernández, J.
Su, F.
Lin, K.
Clarke, Robert B
Caldas, C.
Arribas, J.
Michiels, S.
García-Sanz, A.
Turner, N. C.
Prat, A.
Nuciforo, P.
Dienstmann, R.
Verma, C. S.
Lopez-Bigas, N.
Scaltriti, M.
Arnedos, M.
Saura, C.
Serra, V.
Affiliation
Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, SpainIssue Date
2022
Metadata
Show full item recordCitation
Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, et al. Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER(+) breast cancer. Nature communications. 2022 Nov 14;13(1):6928. PubMed PMID: 36376284. Epub 2022/11/15. eng.Journal
Nature CommunicationsDOI
10.1038/s41467-022-34580-3PubMed ID
36376284Additional Links
https://dx.doi.org/10.1038/s41467-022-34580-3Type
ErratumLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41467-022-34580-3
Scopus Count
Collections
Related articles
- High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER(+) breast cancer.
- Authors: Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, Ibrahimi N, Kannan S, Mina L, Herrera-Abreu MT, Òdena A, Sánchez-Guixé M, Capelán M, Azaro A, Bruna A, Rodríguez O, Guzmán M, Grueso J, Viaplana C, Hernández J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, Michiels S, García-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V
- Issue date: 2022 Sep 7
- Comparative analysis of Rb1, P16 and ER as diagnostic, prognostic and potential targets for therapeutic agents in ovarian epithelial tumors: an immunohistochemical study of 130 ovarian carcinomas.
- Authors: Ferguson DC, Long DJ, Smith MC, Craig-Owens LD, Means J, Fadare O, Desouki MM
- Issue date: 2015 Jun 5
- Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
- Authors: Xi J, Ma CX
- Issue date: 2020 May 16
- LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer.
- Authors: Jin X, Ge LP, Li DQ, Shao ZM, Di GH, Xu XE, Jiang YZ
- Issue date: 2020 May 11
- Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
- Authors: Ogata R, Kishino E, Saitoh W, Koike Y, Kurebayashi J
- Issue date: 2021 Jan